Results 1 to 10 of about 16,193 (191)

Genetic Variation of G6PD and CYP2D6: Clinical Implications on the Use of Primaquine for Elimination of Plasmodium vivax

open access: yesFrontiers in Pharmacology, 2021
Primaquine, an 8-aminoquinoline, is the only medication approved by the World Health Organization to treat the hypnozoite stage of Plasmodium vivax and P. ovale malaria.
Alexandra G. A. Stewart   +3 more
doaj   +1 more source

Safety of single-dose primaquine as a Plasmodium falciparum gametocytocide: a systematic review and meta-analysis of individual patient data

open access: yesBMC Medicine, 2022
Background In 2012, the World Health Organization (WHO) recommended single low-dose (SLD, 0.25 mg/kg) primaquine to be added as a Plasmodium (P.) falciparum gametocytocide to artemisinin-based combination therapy (ACT) without glucose-6-phosphate ...
Kasia Stepniewska   +44 more
doaj   +1 more source

Effects of co-treatment of Plasmodium berghei-infected mice with aqueous extract of Ocimum gratissimum leaves and primaquine on glucose-6-phosphate dehydrogenase activity, hematological, and antioxidant parameters

open access: yesJournal of Ayurveda and Integrative Medicine, 2022
Background: It has been observed that most malaria patients especially G6PD-deficient patients usually experience oxidative stress and severe anemia when treated with primaquine.
Shedrach Kanu C   +3 more
doaj   +1 more source

Optimal timing of primaquine to reduce Plasmodium falciparum gametocyte carriage when co-administered with artemether–lumefantrine

open access: yesMalaria Journal, 2020
Background Primaquine is an important gametocytocidal drug that is combined with conventional malaria treatment for prevention of Plasmodium falciparum malaria transmission.
Seif Shekalaghe   +7 more
doaj   +1 more source

Simultaneous and enantiospecific quantification of primaquine and carboxyprimaquine in human plasma using liquid chromatography-tandem mass spectrometry

open access: yesMalaria Journal, 2022
Background The enantiomers of the 8-aminoquinoline anti-malarial primaquine have different pharmacological properties. Development of an analytical method for simultaneous quantification of the enantiomers of primaquine and its metabolite ...
Warunee Hanpithakpong   +3 more
doaj   +1 more source

5-Phenoxy Primaquine Analogs and the Tetraoxane Hybrid as Antimalarial Agents

open access: yesMolecules, 2021
The rapid emergence of drug resistance to the current antimalarial agents has led to the urgent need for the discovery of new and effective compounds.
Somruedee Jansongsaeng   +4 more
doaj   +1 more source

Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases

open access: yesMalaria Journal, 2021
Background The relapsing nature of Plasmodium vivax infection is a major barrier to its control and elimination. Factors such as adequate dosing, adherence, drug quality, and pharmacogenetics can impact the effectiveness of radical cure of P.
Anielle de Pina-Costa   +12 more
doaj   +1 more source

Single dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission in Cambodia: An open-label randomized trial. [PDF]

open access: yesPLoS ONE, 2017
BACKGROUND:Single low dose primaquine (SLD PQ, 0.25mg/kg) is recommended in combination with artemisinin-based combination therapy (ACT) as a gametocytocide to prevent Plasmodium falciparum transmission in areas threatened by artemisinin resistance.
Jessica T Lin   +16 more
doaj   +1 more source

Primaquine

open access: yesReactions Weekly, 2006
europepmc   +3 more sources

Formation primaquine-5,6-orthoquinone, the putative active and toxic metabolite of primaquine via direct oxidation in human erythrocytes

open access: yesMalaria Journal, 2019
Background The activity and haemolytic toxicity associated with primaquine has been linked to its reactive metabolites. The reactive metabolites are thought to be primarily formed through the action of cytochrome P450-mediated pathways.
Pius S. Fasinu   +9 more
doaj   +1 more source

Home - About - Disclaimer - Privacy